Primary immunodeficiency and chronic mucocutaneous candidiasis: pathophysiological, diagnostic, and therapeutic approaches
Main Article Content
Keywords
candidiasis, chronic mucocutaneous candidiasis, primary immunodeficiency, IL-17, STAT1 GOF
Abstract
Chronic mucocutaneous candidiasis (CMC) is characterized by a chronic or recurrent non-invasive infection, mainly due to Candida albicans, in skin, nails, and mucous membranes, associated in some cases with autoimmune manifestations. The key immune defect is a disruption of the action of cytokine IL-17, whose most common genetic etiology is STAT1 gene gain-of-function (GOF) mutations. The initial appropriate treatment for fungal infections is with azoles. However, the frequent occurrence of drug resistance is the main limitation. Therefore, identification of the underlying inborn error if immunity in CMC may allow to widen therapeutic options aimed at restoring immunological function. Type I and II Janus kinase-inhibitors have been shown to control CMC in cases associated with STAT1 GOF. In this review, we delve into the pathogenesis of CMC and the underlying immune mechanisms. We describe the reported genetic defects in which CMC is the main manifestation. Diagnostic and therapeutic approaches for these patients are also offered.
References
2. Puel A, Picard C, Cypowyj S, Lilic D, Abel L, Casanova JL. Inborn errors of mucocutaneus immunity to Candida albicans in humans: a role for IL-17 cytokines. Curr Opin Immunol. 2010;22(4):467–474. 10.1016/j.coi.2010.06.009
3. Toubiana J, Okada S, Hiller J, Oleastro M, Lagos Gomez M, Aldave Becerra JC, et al. Heterozygous STAT1 gain-of-function mutations underlie an unexpectedly broad clinical phenotype. 2016;127(25):3154–3165. 10.1182/blood-2015-11-679902
4. Puel A, Cypowyj S, Bustamante J, Wright J F, Liu L, Lim HK, et al. Chronic mucocutaneous candidiasis in humans with inborn errors of interleukin-17 immunity*. Science 2011;332: 65–68. 10.1126/science.1200439
5. Bousfiha A, Jeddane L, Picard C, Al-herz W, Ailal F, Chatila T, et al. Human inborn errors of immunity: 2019 update of the IUIS phenotypical classification. J Clin Immunol. 2020;40(1):66–81. 10.1007/s10875-020-00758-x
6. Richardson JP, Moyes DL. Adaptive immune responses to Candida albicans infection. Virulence. 2015;6(4):327–337. 10.1080/21505594.2015.1004977
7. Mihai G. Netea, Neil A.R. Gow, Carol A. Munro, Steven Bates, Claire Collins, Gerben Ferwerda, et al. Immune sensing of Candida albicans requires cooperative recognition of mannans and glucans by lectin and Toll-like receptors. 2006;116(6):1642–1650. 10.1172/JCI27114
8. Ferwerda B, Ferwerda G, Platinga TS, Willment J A, van Spriel A B, Venselaar H, et al. UKPMC Funders Group author manuscript human dectin-1 deficiency and mucocutaneous fungal infections. N Engl J Med. 2009;361(18):1760–1767. 10.1056/NEJMoa0901053
9. Mengesha B, Conti H. The role of IL-17 in protection against mucosal Candida infections. J Fungi. 2017;3(4):52. 10.3390/jof3040052
10. Li X, Bechara R, Zhao J, McGeachy MJ, Gaffen SL. IL-17 receptor-based signaling and implications for disease. Nat Immunol. 2019;20(12):1594–1602. 10.1038/s41590-019-0514-y
11. Hernández-Santos N, Gaffen SL. Th17 cells in immunity to Candida albicans. Cell Host Microbe. 2012;11(5):425–435. 10.1016/j.chom.2012.04.008
12. Green L, Dolen WK. Chronic candidiasis in children. Curr Allergy Asthma Rep. 2017;17(5):31. 10.1007/s11882-017-0699-9.
13. Al-Shaikhly T, Ochs HD. Hyper IgE syndromes: clinical and molecular characteristics. Immunol Cell Biol. 2019;97(4):368–379. 10.1111/imcb.12209
14. Schimke LF, Sawalle-Belohradsky J, Roesler J, Wollenberg A, Rack A, Borte M, et al. Diagnostic approach to the hyper-IgE syndromes: immunologic and clinical key findings to differentiate hyper-IgE syndromes from atopic dermatitis. J Allergy Clin Immunol. 2010;126(3):611.e1–617.e1. 10.1016/j.jaci.2010.06.029
15. Davidson L, Netea MG, Kullberg BJ. Patient susceptibility to candidiasis–a potential for adjunctive immunotherapy. J Fungi. 2018;4(1):9. 10.3390/jof4010009
16. Grimbacher B, Holland SM, Puck JM. Hyper-IgE syndromes. Immunol Rev. 2005;203:244–250. 10.1111/j.0105-2896.2005.00228.x
17. Bergerson JRE, Freeman AF. An update on syndromes with a Hyper-IgE phenotype. Immunol Allergy Clin N Am. 2019;39:49–61. 10.1016/j.iac.2018.08.007
18. Béziat V, Li J, Lin J X, Ma C, Li P, Bousfiha A, et al. A recessive form of Hyper IgE syndrome by disruption of ZNF341-dependent STAT3 transcription and activity. Sci Immunol. 2018;3(24):eaat4956. 10.1126/sciimmunol.aat4956.
19. Frans G, Moens L, Schaballie H, Eyck L V, Borgers H, Wuyts M, et al. Gain-of-function mutations in signal transducer and activator of transcription 1 (STAT1): chronic mucocutaneous candidiasis accompanied by enamel defects and delayed dental shedding. J Allergy Clin Immunol. 2014;134(5):1209–1213. 10.1016/j.jaci.2014.05.044
20. Yamazaki Y, Yamada M, Kawai T, Morio T, Onodera M, Ueki M, et al. Two novel gain-of-function mutations of STAT1 responsible for chronic mucocutaneous candidiasis disease: impaired production of IL-17A and IL-22, and the presence of anti-IL-17F autoantibody. J Immunol. 2014;193(10):4880–4887. 10.4049/jimmunol.1401467
21. Leiding JW, Okada S, Hagin D, Abinun M, Shcherbina A, Balashov D, et al. Hematopoietic stem cell transplantation in patients with gain-of-function signal transducer and activator of transcription 1 mutations. J Allergy Clin Immunol. 2017;141(2):704.e5–717.e5. 10.26226/morressier.57bc1754d462b80290b4d4d7
22. Akarcan S, Severcan E, Karaca N, Isik E, Aksu G, Migaud M, et al. Gain-of-function mutations in STAT1: a recently defined cause for chronic mucocutaneous candidiasis disease mimicking combined immunodeficiencies. Case Reports Immunol. 2017;2017:1–6. 10.1155/2017/2846928 10.1155/2017/2676403
23. Boisson B, Wang C, Pedergnana V, Wu L, Cypowyj S, Rybojad M, et al. A biallelic ACT1 mutation selectively abolishes interleukin-17 responses in humans with chronic mucocutaneous candidiasis. Immunity. 2013;39(4):676–686. 10.1016/j.immuni.2013.09.002
24. Jhamnani RD, Rosenzweig SD. An update on gain-of-function mutations in primary immunodeficiency diseases. Curr Opin Allergy Clin Immunol. 2017;17(6):391–397. 10.1097/ACI.0000000000000401
25. Tabellini G, Vairo D, Scomodon O, Tamassia N, Ferraro R S, Patrizi O, et al. Impaired natural killer cell functions in patients with signal transducer and activator of transcription 1 (STAT1) gain-of-function mutations. 2017;140(2):553.e4–564.e4. 10.1016/j.jaci.2016.10.051
26. Vargas-Hernández A, Mace EM, Zimmerman O, Zerbe C, Freeman A, Rosenzweing S, et al. Ruxolitinib partially reverses functional natural killer cell deficiency in patients with signal transducer and activator of transcription 1 (STAT1) gain-of-function mutations. J Allergy Clin Immunol. 2018;141(6):2142.e5–2155.e5. 10.1016/j.jaci.2017.08.040
27. Husebye ES, Anderson MS, Kämpe O. Autoimmune polyendocrine syndromes. N Engl J Med. 2018;378(2):1132–1141. 10.1056/NEJMra1713301
28. Nwosu I, Oladiran O, Ogbonna-Nwosu C, Anyata A. Autoimmune polyglandular syndrome type 1: a case report and brief review. J Community Hosp Intern Med Perspect. 2019;9(3):252–254. 10.1080/20009666.2019.1616523
29. Zirilli G, Santucci S, Cuzzupé C, Corica D, Pitrolo E, Salzano G. Peculiarities of autoimmune polyglandular syndromes in children and adolescents. Acta Biomed 2017;88(3):271–275. 10.23750/abm.v%vi%i.5898
30. Bonilla FA, Khan DA, Ballas ZK, Chinen J, Frank M M, Hsu J, et al. Practice parameter for the diagnosis and management of primary immunodeficiency. J Allergy Clin Immunol. 2014;136(5):1186.e78–1205.e78. 10.1016/j.jaci.2015.04.049
31. Ling Y, Cypowyj S, Aytekin C, Galicchio M, Camcioglu Y, Nepesov S, et al. Inherited IL-17RC deficiency in patients with chronic mucocutaneous candidiasis. J Exp Med. 2015; 212(5):619–631. 10.1084/jem.20141065
32. Carey B, Lambourne J, Porter S, Hodgson T. Chronic mucocutaneous candidiasis due to gain-of-function mutation in STAT1. Oral Dis. 2019;25(3):684–692. 10.1111/odi.12881
33. García-García A, Gereda-Martínez D, Deyà-Martínez A, Alsina L. The new scenario of primary immunodeficiencies and the role of the clinical immunologist in the specialised clinic]. An Pediatr (Barc). 2020 Feb;92(2):117-118. doi: 10.1016/j.anpedi.2019.09.006. Epub 2019 Nov 7.
34. Garcia-Prat M, Alvarez-Sierra D, Aguiló-Cucurull A, Salgado-Perandrés S, Briongos-Sebastian S, Franco-Jarava C, et al. Extended immunophenotyping reference values in a healthy pediatric extended immunophenotyping reference values in a healthy pediatric population. Cytom Part B Clin Cytom. 2019;96B:223–233. 10.1002/cyto.b.21728
35. Gavino C, Cotter A, Lichtenstein D, Lejtenyi D, Fortin C, Legault C, et al. CARD9 deficiency and spontaneous central nervous system candidiasis: complete clinical remission with GM-CSF therapy. Clin Infect Dis. 2014;59(1):81–84. 10.1093/cid/ciu215
36. Rautemaa R, Richardson M, Pfaller MA, Perheentupa J, Saxén H. Activity of amphotericin B, anidulafungin, caspofungin, micafungin, posaconazole, and voriconazole against Candida albicans with decreased susceptibility to fluconazole from APECED patients on long-term azole treatment of chronic mucocutaneous candidiasis. Diagn Microbiol Infect Dis. 2008;62(2):182–185. 10.1016/j.diagmicrobio.2008.05.007
37. van de Veerdonk FL, Netea MG. Treatment options for chronic mucocutaneous candidiasis. J Infect. 2016;72:S56–S60. 10.1016/j.jinf.2016.04.023
38. The European Medicines Agency – EMA. Jakavi: Ficha tecnica o resumen de las caracteristicas del producto 1. Agencia Eur Medicam. 2006. https://www.ema.europa.eu/en/documents/product-information/jakavi-epar-product-information_es
39. Bloomfield M, Kanderová V, Paračková Z, Vrabcová P, Svaton M, Fronková E, et al. Utility of ruxolitinib in a child with chronic mucocutaneous candidiasis caused by a novel STAT1 gain-of-function mutation. J Clin Immunol. 2018:38(5);589–601. 10.1007/s10875-018-0519-6
40. Forbes LR, Vogel TP, Cooper MA, Castro-Wagner J, Shussler E, Weinacht K, et al. Jakinibs for the treatment of immune dysregulation in patients with gain-of-function signal transducer and activator of transcription 1 (STAT1) or STAT3 mutations. J Allergy Clin Immunol. 2018;142(5):1665–1669. 10.1016/j.jaci.2018.07.020
41. Meesilpavikkai K, Dik WA, Schrijver B, Nagtzaam N, Posthumus-van Sluijs S, van Hagen M, et al. Baricitinib treatment in a patient with a gain-of-function mutation in signal transducer and activator of transcription 1 (STAT1). J Allergy Clin Immunol. 2018;142(1):328.e2–330.e2. 10.1016/j.jaci.2018.02.045
42. The European Medicines Agency – EMA. Olumiant: Ficha tecnica o resumen de las caracteristicas del producto 1. Agencia Eur Medicam. 2006 https://www.ema.europa.eu/en/documents/product-information/olumiant-epar-product-information_es.
43. Weinacht KG, Charbonnier LM, Alroqi F, Plant A, Qiao Q, Wu H, et al. Ruxolitinib reverses dysregulated T helper cell responses and controls autoimmunity caused by a novel signal transducer and activator of transcription 1 (STAT1) gain-of-function mutation. J Allergy Clin Immunol. 2017;139(5):1629.e2–1640.e2. 10.1016/j.jaci.2016.11.022
44. Aldave JC, Cachay E, Núñez L, Chunga A, Murillo S, Cypowyj S, et al. A 1-year-old girl with a gain-of-function STAT1 mutation treated with hematopoietic stem cell transplantation. J Clin Immunol. 2013;33(8):1273–1275. 10.1007/s10875-013-9947-5